 Clinigen Group has set up an exclusive managed access program in Europe for Humanigens anti-inflammatory drug lenzilumab. Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies and in other inflammatory conditions including rheumatoid arthritis. 